RxDoctor Payments Data

Matthew Jonovich, MD

Interventional Cardiology · Jackson, MINPI 1548378540

Payments from drug & device makers

$4,507in general payments, 2019–2025

Across 183 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$524
  • Boston Scientific$504
  • Inari Medical, Inc.$497
  • W. L. Gore & Associates, Inc.$432
  • Shockwave Medical, Inc$406
  • Novartis$371
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$2506%
  • Food & beverage$4,13992%
  • Education$1173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,507 in reported general payments places this provider in the 35th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$137,600
Medicare patients
574
Services billed
1,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban249$305,687
XareltoRivaroxaban102$132,704
EntrestoSacubitril/Valsartan87$116,756
Repatha SyringeEvolocumab48$54,433
JardianceEmpagliflozin39$42,516
Praluent PenAlirocumab35$23,877
Repatha SureclickEvolocumab23$18,814
Ranolazine ErRanolazine59$12,453
Metoprolol Succinate461$8,568
Rosuvastatin Calcium425$8,491
Atorvastatin Calcium395$6,721
ClopidogrelClopidogrel Bisulfate348$6,629
Losartan Potassium279$3,750
Carvedilol221$2,935
Spironolactone275$2,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$192$305,687249 claims
Johnson & JohnsonXarelto$275$132,704102 claims
NovartisEntresto$371$116,75687 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Jackson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →